From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Patent Granted for Anthrax Elimination System

by Global Biodefense Staff
February 5, 2014

In addition to the patents held for healthcare-based enclosed space disinfection applications, Medizone International, Inc. has now been awarded a patent for its government variant of AsepticSure, intended for use by defense agencies as a response to a biological attack on critical buildings, infrastructure and resources.

“We have been successful in completely eliminating Bacillus atropheus and Bacillus subtilis, both internationally recognized study surrogates for Anthrax, one of the most difficult weaponized pathogens to kill,” explained Dr. Michael E. Shannon, Medizone International’s President. “Being able to eliminate these surrogates for Anthrax with our technology almost assures we now have the ability to remediate critical public infrastructure following a biological attack and restore it to service without damaging important and expensive equipment including communications systems.  Militaries have struggled with this problem for decades and, until now, this simply has not been possible.”

“To now have patent protection granted for this system,” stated Edwin Marshall, Medizone’s CEO, “should allow the Company protected access to a potentially lucrative government market due to the unique capability of AsepticSure’s government variant.”

Medizone International, Inc. is a research and development company advancing systems to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Medizone International’s BSL2A certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, provides a primary research and development platform for the company.

From Our Partners
Tags: AnthraxAwardsBioterrorismConsequence Management

Related Posts

Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Pathogens

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC